Literature DB >> 29587891

Morbidity, mortality and long-term sequelae of West Nile virus disease in Québec.

N Ouhoumanne1, A-M Lowe1, A Fortin1, D Kairy2,3, A Vibien4, J K-Lensch4, T-N Tannenbaum5, F Milord1,6.   

Abstract

We aimed to describe the clinical characteristics of West Nile patients reported in Québec in 2012 and 2013 and to document physical, mental and functional status 24 months after symptom onset according to illness severity. The cases were recruited by a public health professional. Data were collected from public health files, medical records and two standardised phone questionnaires: the Short Form-36 and the Instrumental Activities of Daily Living. In all, 92 persons participated in the study (25 had West Nile fever (WNF), 18 had meningitis and 49 had encephalitis). Encephalitis participants were older, had more underlying medical conditions, more neurological symptoms, worse hospital course and higher lethality than meningitis or WNF participants. Nearly half of the surviving hospitalised encephalitis patients required extra support upon discharge. At 24-month follow-up, encephalitis and meningitis patients had a lower score in two domains of the mental component: mental health and social functioning (P = 0.0025 and 0.0297, respectively) compared with the norms based on age- and sex-matched Canadians. Physical status was not affected by West Nile virus (WNV) infection. In addition, 5/36 (15%) of encephalitis, 1/17 (6%) of meningitis and 1/23 (5%) of WNF participants had new functional limitations 24 months after symptom onset. In summary, mental and functional sequelae in encephalitis patients are likely to represent a source of long-term morbidity. Preventive measures should target patients at higher risk of severe illness after WNV infection.

Entities:  

Keywords:  Morbidity/mortality; West Nile virus; sequelae

Mesh:

Year:  2018        PMID: 29587891      PMCID: PMC9184952          DOI: 10.1017/S0950268818000687

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  24 in total

1.  Long-term clinical and neuropsychological outcomes of West Nile virus infection.

Authors:  Paul J Carson; Patrick Konewko; Kimberly S Wold; Paul Mariani; Sunil Goli; Paula Bergloff; Ross D Crosby
Journal:  Clin Infect Dis       Date:  2006-08-10       Impact factor: 9.079

2.  Assessment of older people: self-maintaining and instrumental activities of daily living.

Authors:  M P Lawton; E M Brody
Journal:  Gerontologist       Date:  1969

3.  Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.

Authors:  W M Hopman; T Towheed; T Anastassiades; A Tenenhouse; S Poliquin; C Berger; L Joseph; J P Brown; T M Murray; J D Adachi; D A Hanley; E Papadimitropoulos
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

Review 4.  Long-term sequelae of West Nile virus-related illness: a systematic review.

Authors:  Hetal Patel; Beate Sander; Mark P Nelder
Journal:  Lancet Infect Dis       Date:  2015-07-07       Impact factor: 25.071

5.  Clinical characteristics and functional outcomes of West Nile Fever.

Authors:  John T Watson; Peter E Pertel; Roderick C Jones; Alicia M Siston; William S Paul; Constance C Austin; Susan I Gerber
Journal:  Ann Intern Med       Date:  2004-09-07       Impact factor: 25.391

6.  Neurologic manifestations and outcome of West Nile virus infection.

Authors:  James J Sejvar; Maryam B Haddad; Bruce C Tierney; Grant L Campbell; Anthony A Marfin; Jay A Van Gerpen; Aaron Fleischauer; A Arturo Leis; Dobrivoje S Stokic; Lyle R Petersen
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

7.  Prognosis after West Nile virus infection.

Authors:  Mark Loeb; Steven Hanna; Lindsay Nicolle; John Eyles; Susan Elliott; Michel Rathbone; Michael Drebot; Binod Neupane; Margaret Fearon; James Mahony
Journal:  Ann Intern Med       Date:  2008-08-19       Impact factor: 25.391

8.  Prognosis of West Nile virus associated acute flaccid paralysis: a case series.

Authors:  Jennie Johnstone; Steven E Hanna; Lindsay E Nicolle; Michael A Drebot; Binod Neupane; James B Mahony; Mark B Loeb
Journal:  J Med Case Rep       Date:  2011-08-19

9.  West Nile Virus-associated flaccid paralysis outcome.

Authors:  James J Sejvar; Amy V Bode; Anthony A Marfin; Grant L Campbell; John Pape; Brad J Biggerstaff; Lyle R Petersen
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

10.  Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008.

Authors:  Paul J Carson; Stephanie M Borchardt; Brian Custer; Harry E Prince; Joan Dunn-Williams; Valerie Winkelman; Leslie Tobler; Brad J Biggerstaff; Robert Lanciotti; Lyle R Petersen; Michael P Busch
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

View more
  4 in total

1.  Economic Burden of West Nile Virus Disease, Quebec, Canada, 2012-2013.

Authors:  Najwa Ouhoummane; Eric Tchouaket; Anne-Marie Lowe; Ann Fortin; Dahlia Kairy; Anne Vibien; Jessica Kovitz-Lensch; Terry-Nan Tannenbaum; François Milord
Journal:  Emerg Infect Dis       Date:  2019-10       Impact factor: 6.883

Review 2.  West Nile Disease Symptoms and Comorbidities: A Systematic Review and Analysis of Cases.

Authors:  Maria Bampali; Konstantinos Konstantinidis; Emmanouil E Kellis; Theodoti Pouni; Ioannis Mitroulis; Christine Kottaridi; Alexander G Mathioudakis; Apostolos Beloukas; Ioannis Karakasiliotis
Journal:  Trop Med Infect Dis       Date:  2022-09-08

3.  Acute and Delayed Deaths after West Nile Virus Infection, Texas, USA, 2002-2012.

Authors:  David C E Philpott; Melissa S Nolan; Nicole Evert; Bonny Mayes; Dawn Hesalroad; Eric Fonken; Kristy O Murray
Journal:  Emerg Infect Dis       Date:  2019-02       Impact factor: 6.883

Review 4.  Neurocognitive impacts of arbovirus infections.

Authors:  Marion Clé; Patrick Eldin; Laurence Briant; Annie Lannuzel; Yannick Simonin; Philippe Van de Perre; André Cabié; Sara Salinas
Journal:  J Neuroinflammation       Date:  2020-08-10       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.